Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.

Work, Elizabeth; Nielsen, Ole Steen; Bentzen, S.; Fode, Kirsten; Palshof, Torben

doi:10.1200/jco.1997.15.9.3030

Cited by 151 publications

(71 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is supported by some phase III data and three meta-analyses based on literature. Interpretation of the phase III trials investigating the timing of TRT is difficult because the definitions of early and late TRT, the types of chemotherapy used, and the radiotherapy schedules employed have varied among trials [22][23][24][25][26][27][28][29][30]. Of the trials performed, three revealed longer survival for early versus late TRT [23, 29,30].…”

Section: Timing Of Radiationmentioning

confidence: 99%

Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms

Stinchcombe

Gore

2010

The Oncologist

View full text Add to dashboard Cite

In the U.S., the prevalence of small cell lung cancer (SCLC) is declining, probably reflecting the decreasing prevalence of tobacco use. However, a significant number of patients will receive a diagnosis of SCLC, and approximately 40% of patients with SCLC will have limited-stage (LS) disease, which is potentially curable with the combination of chemotherapy and radiation therapy. The standard therapy for LS-SCLC is concurrent chemoradiotherapy, and the 5-year survival rate observed in clinical trials is approximately 25%. The standard chemotherapy remains cisplatin and etoposide, but carboplatin is frequently used in patients who cannot tolerate or have a contraindication to cisplatin. Substantial improvements in survival have been made through improvements in radiation therapy. Concurrent chemoradiotherapy is the preferred therapy for patients who are appropriate candidates. The optimal timing of concurrent chemoradiotherapy is during the first or second cycle, based on data from meta-analyses. The optimal radiation schedule and dose remain topics of debate, but 1.5 Gy twice daily to a total of 45 Gy and 1.8 -2.0 Gy daily to a total dose of 60 -70 Gy are commonly used treatments. For patients who obtain a near complete or complete response, prophylactic cranial radiation reduces the incidence of brain metastases and improves overall survival. The ongoing Radiation Therapy Oncology Group and Cancer and Leukemia Group B and the European and Canadian phase III trials will investigate different radiation treatment paradigms for patients with LS-SCLC, and completion of these trials is critical.

show abstract

Section: Timing Of Radiationmentioning

confidence: 99%

Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms

Stinchcombe

Gore

2010

The Oncologist

View full text Add to dashboard Cite

show abstract

“…All of the above-described trials involved patients who received PCI after completion of induction chemotherapy or chemoradiotherapy. There have been two studies giving PCI before chemotherapy [10,11]. However, the optimal application time of brain irradiation in relation to administration of chemotherapy was not systematically evaluated.…”

Section: When To Apply Pci In Sclc?mentioning

confidence: 99%

Prophylactic Cranial Irradiation in Limited-Disease Small-Cell Lung Cancer – Why, When, How Much?

Bohrer

Wenz²

2002

Oncol Res Treat

View full text Add to dashboard Cite

“…Early concurrent thoracic radiation therapy with combination chemotherapy consisting of VP-16/CDDP is a standard treatment for LD-SCLC patients (Perry et al 1987;Pignon et al, 1992;Murray et al, 1993;Jeremic et al, 1997;Work et al, 1997). Twice-daily thoracic radiation therapy and prophylactic cranial irradiation after a CR have recently been added to the standard treatment (Trussi et al, 1999;Takada et al, 2002).…”

Section: Cpt-11-containing Regimens For Ld-sclcmentioning

confidence: 99%

Progress in treatment of small-cell lung cancer: role of CPT-11

Saijo

2003

Br J Cancer

View full text Add to dashboard Cite

Small-cell lung cancer (SCLC) accounts for approximately 15% of all cases of lung cancer and is a particularly aggressive form of lung cancer characterised by a poor prognosis, rapid tumour growth, and early metastasis. Roughly, two-thirds of patients with SCLC present with extensive disease (ED) and one-third with limited disease (LD). Combination chemotherapy is the most effective treatment modality for SCLC, and several new agents, including carboplatin, ifosfamide, taxans, and topotecan, have been demonstrated to be active; however, there are no data on the survival benefit of these drugs. A CPT-11 þ cisplatin regimen has shown improvement in overall survival over the global gold standard regimen, etoposide þ cisplatin (Japanese Clinical Oncology Group: JCOG 9511), and three confirmatory randomised controlled trials are in progress to determine the reproducibility of the JCOG 9511 study. JCOG is evaluating the role of CPT-11 and a new triplet regimen containing CPT-11 in limited-stage SCLC. Strategies and the current protocols of the JCOG are presented and discussed. In the future, it will be essential to evaluate molecular target-based drugs for LD and ED SCLC with new standard combination chemotherapy regimens that include CPT-11.

show abstract

Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.

Abstract: Timing of CI did not significantly influence the incidence of in-field recurrences, CNS recurrences, or overall survival.

Cited by 151 publications

References 14 publications

Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms

Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms

Prophylactic Cranial Irradiation in Limited-Disease Small-Cell Lung Cancer – Why, When, How Much?

Progress in treatment of small-cell lung cancer: role of CPT-11

Contact Info

Product

Resources

About